Dr Kym Lowes
Honorary (Principal Fellow)
Department of Medical Biology (WEHI)
43 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Dual plasmepsin IX and X inhibitors are refractory to development of resistance
DOI: 10.1371/journal.ppat.10140682026
Journal article
Global analysis of cancer cell responses to USP9X inhibition
DOI: 10.1038/s44318-026-00742-y2026
Journal article
Correction to “Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents”
DOI: 10.1021/acs.jmedchem.6c007782026
Journal article
Novel Scaffold Unlocks Potent Cross-Peptidase and Cross-Species Inhibitors as Promising Antimalarial Agents
DOI: 10.1021/acs.jmedchem.5c027432026
Journal article
MK-7602: a potent multi-stage dual-targeting antimalarial
DOI: 10.1016/j.ebiom.2025.1060612025
Journal article
Divergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity
DOI: 10.1371/journal.ppat.10134682025
Journal article
Differential regulation of BAX and BAK apoptotic activity revealed by small molecules
DOI: 10.1126/sciadv.adr8146
RECENT SCHOLARLY WORKS
2025
Journal article
A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
DOI: 10.1038/s41467-025-57905-42024
Journal article
Mutational profiling of SARS-CoV-2 papain-like protease reveals requirements for function, structure, and drug escape
DOI: 10.1038/s41467-024-50566-92023
Journal article
The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
DOI: 10.1042/BCJ20230035